With approximately two - thirds
of responders to AF - 219
treatment showing more than a 50 % reduction in cough frequency, we plan to advance the development
of AF - 219 by initiating a
Phase 2b study in patients with chronic cough early
next year and to initiate other studies in preparation for registration studies.»
Then it's like the
next group
of doctors, primarily care, family medicine, that realize that something's wrong, maybe they're working in a hospital that has a McDonald's or Burger King in it, maybe they are just sick
of seeing people getting sicker and sicker, and putting them on a
treatment plan where there's literally no ends in sight, and having sort
of a moment where they realize this is the kind
of medicine they want to practice, but they don't know how to get there, let's bring those people across, let's get them set up with a functional micropractice, and then
phase 2 could be something like what you're talking about.
Next, the
treatment phase, the patients received up to 25 sessions
of individual ST. WHO - QOL and The Global Assessment
of Functioning (GAF) were the primary outcome measures.